Combatting the 21st century global public health problems through revolutionary i-αVLP Technology.

SEE OUR TECHNOLOGY
1503, 2016

VLP Therapeutics Appoints Louis M. Weiner, M.D., Director of Georgetown Lombardi Comprehensive Cancer Center as Scientific Advisor

Gaithersburg, Md.— March 14, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and

2702, 2016

VLP Therapeutics Wins Maryland Industrial Partnerships Grant Award

Gaithersburg, Md.-- (PR NEWS WIRE) — February 27, 2016 -- VLP Therapeutics LLC (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next-generation antibody agents based upon

802, 2016

VLP Therapeutics Announces Issuance of U.S. Composition of Matter Patent for i-α Virus Like Particle Platform Technology – Intellectual Property Estate Strengthens Malaria, Dengue and Zika Virus Disease Program –

Gaithersburg, Md.—February 8, 2016 -- VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,249,191, Virus Like Particle Composition. The patent protects key

Vaccines are one of the most important inventions in the past centuries. The successful vaccines save millions of lives by eradicating the epidemic and pandemic diseases. I left the research field and formed VLP Therapeutics because I am committed to developing the next generation vaccine technology to treat the diseases that currently lack effective treatment. We believe that our i-αVLP vaccine technology has a potential to create a breakthrough treatments and make significant contributions to the improvement of global public health.